SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference
09 June 2021 - 6:03AM
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company
dedicated to solving musculoskeletal disorders of the sacropelvic
anatomy, today announced that the company will be participating in
the upcoming 2021 JMP Securities Life Sciences Conference.
Management is scheduled to present on Thursday, June 17 at 2:30
p.m. Eastern Time / 11:30 a.m. Pacific Time.
Interested parties may access a live and archived webcast of the
presentation on the “Investors” section of the company’s website
at: www.si-bone.com
About SI-BONE, Inc.SI-BONE is a
medical device company that pioneered minimally invasive surgery of
the SI joint with the iFuse Implant System. Studies have shown that
the SI joint can be a source of pain in 15% to 30% of chronic low
back pain. The iFuse Implant™, commercially available since 2009,
is the only SI joint fusion device supported by multiple
prospective clinical studies, including two randomized controlled
trials, showing improved pain, patient function and quality of life
resulting from treatment. There are over 90 peer-reviewed
publications demonstrating the safety, durable effectiveness, and
biomechanical and economic benefits unique to the iFuse Implant
(www.si-bone.com/results). This body of evidence has enabled
multiple government and private insurance payors to establish
coverage of the SI joint fusion procedure exclusively when
performed with the iFuse Implant System.
The iFuse Implant System is intended for
sacroiliac fusion for conditions including sacroiliac joint
dysfunction that is a direct result of sacroiliac joint disruption
and degenerative sacroiliitis. This includes conditions whose
symptoms began during pregnancy or in the peripartum period and
have persisted postpartum for more than 6 months. The iFuse Implant
System is also intended for sacroiliac fusion to augment
stabilization and immobilization of the sacroiliac joint in
skeletally mature patients undergoing sacropelvic fixation as part
of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant
System is intended for sacroiliac fusion in acute, non-acute, and
non-traumatic fractures involving the sacroiliac joint. There are
potential risks associated with the iFuse Implant System. It may
not be appropriate for all patients and all patients may not
benefit.
SI-BONE and iFuse Implant System are registered trademarks of
SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 06082021
Investor Contact:Matt Bacso,
CFAinvestors@SI-BONE.com
Media Contact:Joe
Powersjpowers@si-bone.com
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jun 2024 to Jul 2024
SI BONE (NASDAQ:SIBN)
Historical Stock Chart
From Jul 2023 to Jul 2024